IL17A and breast cancer: In non -small-cell-lung-cancer (NSCLC), interleukin 17 (IL-17) induced the expression of CCL20, and their concomitant expression promoted the disease progression [112].In breast cancer, evidence has shown that the tumor-promoting functions of CCL20 can be regulated by human antigen R (HuR), Cbp/P300 interacting transactivator with Glu/Asp-rich carboxyl-terminal domain 2(CITED2) and tumor necrosis factor-alpha (TNF-α) (Table 2).